BioTools Innovator

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

BacStitch DNA is a DNA assembly revolution that accelerates protein, pathway, and cellular engineering.

BioRaptor is developing an operating system tailored for biotech and biopharma firms, focusing on empowering scientists through the use of artificial intelligence. The platform integrates and harmonizes data from various sources, enabling scientists to leverage this information to design more effective experiments and gain insights that enhance their understanding of experimental outcomes. By facilitating data-driven decision-making, BioRaptor aims to improve productivity and provide valuable insights that can accelerate the research and development processes within the biotech sector.

Atomnaut is a developer of advanced microscopy technology, specifically a 3D atomic resolution microscope that utilizes unique projection technology to accurately identify and detect the position of atoms in three-dimensional space. This innovative tool enables detailed imaging, analysis, sequencing, and design at the atomic level, allowing scientists to understand and manipulate materials more effectively. The company specializes in materials engineering and offers a range of advanced materials, including silicon transistors, high-strength steels, nanowires, quantum dots, tungsten alloys suitable for fusion or aerospace applications, and nanostructured light and strong aluminum alloys. Atomnaut's technology supports a variety of scientific and engineering applications, pushing the boundaries of materials research and development.

TeraCyte Analytics specializes in predicting human medication response. It achieves this by analyzing single-cell dynamics, providing pharmaceutical researchers with valuable insights to understand and forecast cellular reactions to new drugs or perturbations. This enables informed decision-making in drug development and treatment strategies.

Argome is a smart nanoparticle platform that allows for a uniform next-generation multiomic approach.

Scribe Biosciences specializes in single-cell analysis tools that enhance clinical and research applications. The company employs its proprietary technology, Printed Droplet Microfluidics (PDM), which allows for flexible and reconfigurable fluid handling at the picoliter scale. By utilizing fluorescence-activated microfluidic droplet sorting along with a specialized substrate, Scribe Biosciences can manipulate single cells and fluid aliquots with high throughput. This innovative approach aids researchers and healthcare professionals in gaining insights into various processes, particularly those related to infectious diseases and cancer.

BennuBio, Inc. is a technology company specializing in the development of flow cytometry equipment designed for the sorting and analysis of cells and particles in various applications, particularly those requiring the recovery of rare cells. The company offers The Velocyt system, which enables the detection of rare events such as activated T cells, circulating tumor cells, and fetal cells in maternal blood, supporting advancements in personalized medicine and drug discovery. Additionally, BennuBio provides spheroid generation systems and high-volume sorting systems, along with technical and application support services. Founded in 2018 and based in Albuquerque, New Mexico, BennuBio focuses on delivering innovative cell analysis solutions that accommodate a wide range of sample sizes and particle dimensions.

Switchback Systems is an early-stage startup founded in 2019 by Mary Noe, specializing in the development of a scalable DNA synthesis platform. The company aims to significantly reduce the time, cost, and waste associated with nucleic acid applications. Its innovative platform utilizes advanced technologies to facilitate the use of cell structure as a data storage medium. By offering a benchtop DNA printer, Switchback Systems provides the healthcare industry with on-demand biological discovery capabilities, catering to the needs of laboratories and enhancing their research efficiency.

Aureka Biotechnologies is an innovative biotech company focused on transforming the pharmaceutical industry to improve healthcare accessibility. The firm has developed a therapeutic discovery platform that utilizes advanced machine learning and artificial intelligence technologies to streamline the therapeutic design process. By digitalizing drug development at scale, Aureka aims to identify and design potential drug candidates more efficiently, ultimately leading to the creation of novel treatments. This approach seeks to significantly lower costs and reduce the time required for bringing new therapies to market, thereby enhancing the overall effectiveness of the pharmaceutical sector in addressing various health challenges.

CRISPRQC develops an analytics platform that enhances the efficiency and effectiveness of CRISPR gene editing. This platform is built around the CRISPR-Chip, a unique device that directly measures CRISPR activity. By simulating the gene editing process prior to cell introduction, CRISPRQC provides essential data and insights that are crucial for quality control and maximizing the potential of CRISPR technology. The platform empowers scientists to increase editing efficiency and formulate strategies for improved outcomes at the cellular level, ultimately accelerating the development of CRISPR-based products.

ReelReactor specializes in the development of continuous reactor technologies aimed at enhancing the throughput, efficiency, and quality of chemical, pharmaceutical, and biological products and therapies. This innovative technology has the potential to transform manufacturing processes across various industries by reducing costs and improving the consistency and quality of products. As a result, ReelReactor's solutions may facilitate greater accessibility to vital therapies, ultimately benefiting a wide range of sectors reliant on high-quality manufacturing.

mk2 Biotechnologies uses a synthesis process to design, synthesize, and research peptides and proteins. Their process allows the scalable and production of purity peptides and proteins for a range of applications.

Aopia Biosciences is a biotechnology company dedicated to advancing bioengineering solutions for biomedical research, diagnostics, and therapeutic applications. The company specializes in ultra-high sensitivity biomarker detection, which is crucial for early disease diagnosis and monitoring treatment efficacy. Aopia's platform supports research focused on extracellular vesicles (EVs) and exosomes, providing innovative tools that enhance the understanding of disease mechanisms and improve patient outcomes. Through its cutting-edge technologies, Aopia aims to facilitate significant advancements in the fields of diagnostics and therapeutics.

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

PAK BioSolutions specializes in the manufacture of biopharmaceuticals, focusing on automation equipment and single-use flow kits designed for continuous production processes. The company offers a range of comprehensive solutions that include automated systems and consumables suitable for both laboratory and GMP facilities. By implementing these continuous processes, PAK BioSolutions aims to enhance productivity for its clients while reducing capital costs and minimizing space requirements. Additionally, the company provides consulting services to further support its clients in optimizing their manufacturing operations.

Andson Biotech specializes in developing innovative Process Analytical Technologies (PAT) tailored for advanced biomanufacturing, particularly in cell-based bioprocesses. The company has created a proprietary secretome analysis system that streamlines and enhances traditional analytical measurements typically conducted through mass spectrometry workflows. By leveraging its core technologies, Andson Biotech aims to accelerate and simplify the drug discovery process, enabling the efficient development of assays. This commitment helps bring advanced therapies, including recombinant proteins, monoclonal antibodies, and vaccines, to market more rapidly, ultimately benefiting healthcare professionals and patients alike.

Clara Biotech is focused on developing a platform technology for the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsies for early detection of various diseases, including cancer and Alzheimer's Disease. Unlike traditional methods that require lengthy ultra-centrifugation, Clara's platform can extract pure and viable exosomes from any biofluid source efficiently. This innovative process enhances the potential for precision medicine by enabling targeted drug delivery directly to specific cells. Additionally, Clara Biotech's technology supports the development of unique liquid biopsy assays, improving the accuracy of disease detection and addressing challenges faced by biopharma companies in the medical field. Overall, Clara Biotech aims to advance research into clinical applications, bridging the gap between laboratory findings and patient care through its exosome-based solutions.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Atom Bioworks focuses on developing a pattern-recognition enabled platform that combines DNA, antibody mimics, and advanced computational techniques for the detection and treatment of infectious diseases and cancer. The platform utilizes computational biology, quantum chemistry, software, and machine learning to identify specific surface protein patterns associated with diseases. By creating corresponding pattern-matching constructs, Atom Bioworks aims to enhance researchers' capabilities in early diagnosis and therapeutic interventions, ultimately improving medical applications in the fight against infectious diseases and cancer.

Ananda Devices is a biotech company specializing in advanced nano-organization technology aimed at enhancing research and development in the pharmaceutical, food, and cosmetic industries. This proprietary technology facilitates the innervation of various tissue types and allows for the miniaturization of existing biological models. By creating co-culture models that provide access to individual components, Ananda Devices enables researchers and physicians to generate detailed and physiologically relevant data tailored to their specific requirements.

Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.

Opera Bioscience is a biotechnology company focused on providing researchers with high-quality and cost-effective reagents and recombinant proteins. The company specializes in a fermentation process that produces microbial protein products at high purity levels. This innovative approach allows scientists to source essential proteins, growth factors, and reagents quickly and economically, facilitating their bioprocesses. By ensuring accessibility to these critical materials, Opera Bioscience aims to support advancements in research and development within the biotechnology sector.

Ferrologix is a startup emerging from the University of California, Los Angeles, founded in the lab of Professor Dino Di Carlo in the bioengineering department. The company specializes in a magnetic-based technology that utilizes a unique instrument and disposable cartridges to transport, filter, and organize single cells for precise analysis and therapeutic production. By pioneering a method known as Digital Magnetic Sorting, Ferrologix aims to enhance the efficiency of precision medicine research, next-generation diagnostics, and cellular therapies. Its technology specifically addresses the challenges faced in the cellular therapy market, offering a solution that balances cost, purity, and yield in cell separation processes. This enables research institutions to reduce costs and expand their capabilities, ultimately accelerating the development of innovative cell therapies.

Zymvol accelerates the discovery & development of new industrial enzymes through computer simulations.

GenNext Technologies is a provider of instrumentation, software, and services specifically designed for structural biology researchers in the biopharmaceutical industry. The company focuses on developing protein and contract research footprinting systems, which assist pharmaceutical researchers in studying biopharmaceutical structures, interactions, folding, aggregation, and formulation. By enhancing research capabilities in structural biology, GenNext aims to accelerate biopharmaceutical development and improve therapeutic efficacy and safety. This platform enables clients to conduct advanced research within the biotechnology field, supporting their efforts to innovate and advance drug development processes.

Cellbox Solutions is a technology company that specializes in innovative logistical solutions for the global BioMed industry. The company has developed a carbon dioxide incubator aimed at enhancing the storage, isolation, handling, and analysis of biological materials. This incubator supports the proper management of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the safe transport of living cells via roads, rails, or airways, Cellbox Solutions assists healthcare providers in their efforts to deliver advanced therapies and improve patient treatment outcomes.

CellChorus specializes in advanced single-cell analysis for biopharmaceutical companies, utilizing its proprietary TIMING™ platform. This visual artificial intelligence technology enables dynamic evaluation of cell activation, killing, and movement over time. By integrating data on kinetics and interactions with insights from single-cell RNA sequencing and flow cytometry, CellChorus provides healthcare organizations with a comprehensive understanding of cellular function, state, and phenotype. This innovative approach aims to enhance the development and efficacy of immuno-oncology therapies and other medical treatments.

DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

Dalton Bioanalytics specializes in developing advanced analytical technology aimed at transforming blood analysis into a more efficient and cost-effective process. By digitizing the biochemical composition of blood, the company provides a comprehensive array of actionable health insights, addressing the limitations of traditional laboratory testing. This technology enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules, through a single assay. Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine. Founded in 2019, the company is headquartered in Los Angeles, California.

RealSeq Biosciences specializes in innovative, proprietary technologies for constructing unbiased small RNA and miRNA libraries for next-generation sequencing (NGS). Their core product, RNA fragmentomics technology, enables real-time disease detection, enhancing diagnosis and treatment in cancer and infectious diseases. This technology facilitates biomarker discovery, liquid biopsy, and single-cell analysis, ultimately improving patient outcomes through innovative RNA-based services.

xMD Diagnostics, based in Annapolis, Maryland, specializes in biotechnology within the healthcare sector. The company develops molecular diagnostics tools that use high-throughput microdissection technology to improve cancer diagnosis and management. These tools are designed to isolate, procure, and enrich cells of interest from biopsy and other specimen samples. This process facilitates various downstream analyses, including PCR, genomic or proteomic testing, and next-generation sequencing. By enhancing the capabilities of clinical and research laboratories, xMD Diagnostics supports pathologists, oncologists, and other healthcare professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Elemental Machines, Inc., founded in 2014 and based in Cambridge, Massachusetts, specializes in providing a smart lab platform designed to enhance laboratory operations in science-based industries. The company's innovative technology continuously monitors equipment and environmental variables, delivering data-driven insights that foster improved research, development, and manufacturing outcomes. By utilizing intelligent sensors, the platform visualizes the entire testing environment and issues alerts for any anomalous results, thereby ensuring experimental reproducibility. This capability allows clients to refine and accelerate their work across all phases of product innovation, ultimately leading to greater clarity, transparency, and consistency in laboratory processes.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Enrich Biosystems focuses on developing innovative technologies for cell imaging, analysis, and capture, aimed at advancing cell-based therapies and precision medicine. The company has created a unique single-cell isolation platform that operates without microfluidics, utilizing dissolvable microwells and visual enrichment techniques. This approach addresses significant challenges faced by existing technologies, offering a streamlined workflow for cell culturing and kinetics profiling. Enrich Biosystems' solutions enhance biomedical research by allowing healthcare professionals to efficiently capture and analyze individual cells based on their functions, thereby facilitating progress in various critical life science applications.